Werewolf Therapeutics Inc (HOWL) News

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or...

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical...

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of...

Form 8-K - Current report

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

-  WTX-124 was shown to be clinically active and generally well-tolerated in patients who were...

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and...